I am today updating the House on the severe shortage of radioisotopes that the UK is facing. The affected radioisotopes are mainly used for diagnosing cancers, including prostate and breast cancer. It is also used for imaging of organ function in scans, including for the heart. Despite efforts by my Department and NHS England to limit the negative impacts of this shortage, there will be delays to patient access to services relying on the impacted radioisotopes, including cancellations.
This shortage is due to a temporary reduction in the production of molybdenum-99 which is used to generate technetium-99m. The radioisotope technetium-99m is used safely for diagnostics in the NHS. This issue is impacting not only the UK, but countries across Europe, and worldwide.
The shortage of molybdenum-99 is caused by a sudden global disruption of manufacturing capacity, with a number of the nuclear reactors used to produce these elements being out of service. There are six trusted research reactors globally for the supply of molybdenum-99, none of which are in the UK. Some of these reactors are currently out of service to allow for critical repair work; this is essential work necessary for the safe running of the research reactors. Two of the impacted reactors are expected to restart production during the second week of November, with deliveries from these reactors expected to resume in mid-November. My Department, together with relevant experts, is working closely with suppliers to support the process to restart the affected reactors as soon as possible.
There will remain a significantly constrained supply of these radioisotopes to the UK from the remaining reactors. Radioisotopes give off radiation and undergo a process of decay, which means they cannot be stored or kept in reserve. Our priority is to minimise the impact on patients as much as possible. Therefore, my Department is working closely with suppliers, clinical experts, NHS England and devolved Governments to support the allocation of deliveries and ensure there is equitable and fair access across the UK to the constrained supply of stock that is available. NHS England is supporting trusts and hospitals to share available supply and ensure that critical patients are given priority. Guidance is being issued to ensure that patients with the most critical need are prioritised. If any patient is concerned about their treatment, they should discuss this with their clinician at the earliest opportunity.
I know how difficult this will be for affected patients while we face this supply issue. This issue is different in nature to normal supply chain problems due to the unique challenges radioisotope shortages present. My Department is working closely with suppliers and relevant experts to resolve the supply issue as soon as possible. I will continue to keep Parliament updated on our progress to resolve this severe shortage.
[HCWS170]